Novelix Pharmaceuticals Ltd

Novelix Pharmaceuticals Other Announcement

Novelix Pharmaceuticals informs shareholders that the Annual Report for FY 2025-26 and the 32nd AGM notice are available on the Company's website.

Novelix Pharmaceuticals Annual Report

Novelix Pharmaceuticals filed its Annual Report and AGM Notice for the financial year 2025-26. The 32nd Annual General Meeting is scheduled for September 30, 2026.

Novelix Pharmaceuticals Annual General Meeting

Novelix Pharmaceuticals Limited will hold its 32nd Annual General Meeting on September 30, 2026. The company has fixed September 23, 2026, as the cut-off date for e-voting.

Novelix Pharmaceuticals Management Change

Novelix Pharmaceuticals Limited appointed Mr. Gnana Prakash Gattu as Whole-time Director for a five-year term. The appointment, effective August 29, 2026, awaits shareholder approval.

Execution

5 years

Novelix Pharmaceuticals Board Meeting Outcome

Novelix Pharmaceuticals Ltd approved the AGM notice and appointed Mr. Gnana Prakash Gattu as a Whole-time Director in its board meeting outcome.

Novelix Pharmaceuticals Board Meeting Date

Novelix Pharmaceuticals Limited will hold a board meeting on August 29, 2026, to discuss the AGM notice, annual report, and a director appointment.

Novelix Pharmaceuticals Capacity Expansion: ₹0.03 Cr Investment

Novelix Pharmaceuticals executed a five-year land lease for micro algae cultivation in Telangana. The company will pay a monthly rent of Rs. 5,000 for 0.925 acres.

Value

₹0.03 Cr

Execution

5 years

Novelix Pharmaceuticals Other Announcement

Novelix Pharmaceuticals filed its Statement of Deviation and Variation for the quarter ended June 30, 2026, reporting no deviations in fund utilization.

Novelix Pharmaceuticals Q1 FY27 Results: Net Profit ₹1.2 Cr, Up 1100.0% YoY

Novelix Pharmaceuticals Ltd reported revenue from operations of ₹36.9 Cr (+64.7% YoY) and net profit of ₹1.2 Cr (+1100.0% YoY) for Q1 FY27.

Key figure

Net profit ₹1.2 Cr · +1100.0% YoY

Novelix Pharmaceuticals Board Meeting Date

Novelix Pharmaceuticals has scheduled a board meeting for August 13, 2026, to consider and approve the unaudited standalone financial results for the quarter ended June 30, 2026.

Novelix Pharmaceuticals Promoter Buying: ₹13.95 Cr

Novelix Pharmaceuticals promoters acquired 3,37,500 shares worth Rs. 6.75 Crore via warrant conversion. The acquisition increases the promoter group's consolidated equity stake in the company.

Value

₹13.95 Cr

Novelix Pharmaceuticals Capital Structure Change

Novelix Pharmaceuticals allotted 25,00,000 equity shares to promoter group entities following warrant conversion. This increased the promoter group stake from 36.42% to 39.35%.

Novelix Pharmaceuticals Capital Structure Change

Novelix Pharma approved a total equity raise of ₹74.34 Crore through a promoter warrant conversion and a non‑promoter preferential issue. The issue adds 4.5 million shares to its paid‑up capital.

Value

₹74.34 Cr

Novelix Pharmaceuticals Capital Structure Change

Novelix Pharmaceuticals allotted 45,75,000 equity shares, raising approximately Rs. 11.90 Crore. This includes warrant conversions for promoters and a preferential issue to 16 non-promoter investors.

Value

₹11.90 Cr

Novelix Pharmaceuticals Annual General Meeting

Novelix Pharmaceuticals held an Extra Ordinary General Meeting on July 1, 2026. The meeting included a special resolution for issuing equity shares on preferential basis.

Novelix Pharmaceuticals Annual General Meeting

Novelix Pharmaceuticals convened an EGM for July 1, 2026, to approve a ₹6.84 Crore preferential allotment. The capital raise targets non-promoter investors to fund technology transfers.

Value

₹6.84 Cr

Novelix Pharmaceuticals Annual General Meeting

Novelix Pharmaceuticals has scheduled an EGM for July 01, 2026, via video conferencing. The board fixed June 24, 2026, as the cut-off date for shareholder e-voting eligibility.

Novelix Pharmaceuticals Fund Raise of ₹6.84 Cr

Novelix Pharmaceuticals approved a Rs. 6.84 Crore preferential allotment of 12,00,000 equity shares. The capital raise targets non-promoter investors at Rs. 57 per share.

Value

₹6.84 Cr

Novelix Pharmaceuticals Partnership

Novelix Pharmaceuticals signed an agreement with Germany's GMBU e.V. for commercial scale-up of Astaxanthin production. This collaboration follows successful pilot-scale production at Hyderabad facilities.

Novelix Pharmaceuticals Capital Structure Change

Novelix Pharmaceuticals allotted 9,50,000 equity shares to promoter group entities following warrant conversions. The ₹2.81 Crore equity infusion strengthens the company's capital base.

Value

₹2.81 Cr

Novelix Pharmaceuticals Fund Raise

Novelix Pharmaceuticals allotted new equity shares to its promoter group via a preferential offer. This issuance increases promoter stake through a formal regulatory allotment process.

Novelix Pharmaceuticals Capital Structure Change

Novelix Pharmaceuticals promoters converted warrants into 1,50,000 equity shares on May 29, 2026. This conversion increases the total promoter voting shareholding to 2.09%.

Novelix Pharmaceuticals Capital Structure Change

Novelix Pharmaceuticals allotted 28,10,000 equity shares upon warrant conversion, receiving ₹4.22 Crore. This increases the company's paid-up equity capital to ₹23.90 Crore.

Value

₹4.22 Cr

Novelix Pharmaceuticals Fund Raise of ₹16.24 Cr

Novelix Pharmaceuticals reported zero deviation in the utilization of ₹16.25 Crore raised through preferential issues. The Audit Committee reviewed and confirmed the funds were used as intended.

Value

₹16.24 Cr

Novelix Pharmaceuticals Financial Results

Novelix Pharmaceuticals reported a total annual revenue of ₹132.34 Crore and net profit of ₹2.56 Crore for FY26. The results received an unmodified audit opinion.

Value

₹132.3 Cr

Novelix Pharmaceuticals Financial Results

Novelix Pharmaceuticals approved audited FY2026 financial results and received ₹0.42 Crore from warrant conversions. Revenue reached ₹132.34 Crore with a net profit of ₹2.56 Crore.

Value

₹0.42 Cr

Novelix Pharmaceuticals Other Announcement

Novelix Pharmaceuticals declared non-applicability of the Annual Secretarial Compliance Report for FY2026. The company remains exempt due to being below SEBI LODR regulatory thresholds.

Novelix Pharmaceuticals Board Meeting Date

Novelix Pharmaceuticals scheduled a board meeting on May 29, 2026, to approve audited financial results and warrant conversions. Investors should track post-meeting outcomes for strategic updates.

Novelix Pharmaceuticals Other Announcement

Novelix Pharmaceuticals Limited has announced its official website address as https://novelixpharma.com in compliance with SEBI Listing Regulations. The website contains all information required under Regulation 46 of the SEBI LODR Regulations, 2015.

Novelix Pharmaceuticals Debt & Borrowing: ₹0.81 Cr

Novelix Pharmaceuticals Limited submitted its initial disclosure under the SEBI Large Corporate framework for FY 2026-27. As of March 31, 2026, the company reported outstanding borrowings of ₹0.81 Crore. The company confirmed it does not meet the criteria to be identified as a Large Corporate for the current financial year.

Value

₹0.81 Cr